

# Samuel D Vasikaran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2792812/publications.pdf>

Version: 2024-02-01

119  
papers

5,317  
citations

117453

34  
h-index

85405

71  
g-index

120  
all docs

120  
docs citations

120  
times ranked

5283  
citing authors

#	ARTICLE	IF	CITATIONS
1	Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. <i>Osteoporosis International</i> , 2011, 22, 391-420.	1.3	893
2	The assessment of vertebral deformity: A method for use in population studies and clinical trials. <i>Osteoporosis International</i> , 1993, 3, 138-147.	1.3	503
3	International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1271-1274.	1.4	274
4	Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1700-1707.	3.1	247
5	Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. <i>Aids</i> , 2001, 15, 1275-1280.	1.0	154
6	A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. <i>Calcified Tissue International</i> , 2014, 94, 560-567.	1.5	141
7	Methylenetetrahydrofolate Reductase Gene and Coronary Artery Disease. <i>Circulation</i> , 1997, 95, 21-23.	1.6	139
8	The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and Design of an International, Large, Simple, Randomised Trial of Homocysteine-Lowering Multivitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke. <i>Cerebrovascular Diseases</i> , 2002, 13, 120-126.	0.8	138
9	Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. <i>Annals of Clinical Biochemistry</i> , 2006, 43, 23-30.	0.8	119
10	Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis. <i>Annals of Laboratory Medicine</i> , 2012, 32, 105-112.	1.2	113
11	A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: Effect on mood, cognition and quality of life. <i>Neurobiology of Aging</i> , 2006, 27, 141-149.	1.5	107
12	Bisphosphonates: an overview with special reference to alendronate. <i>Annals of Clinical Biochemistry</i> , 2001, 38, 608-623.	0.8	104
13	Clinical usefulness of bone turnover marker concentrations in osteoporosis. <i>Clinica Chimica Acta</i> , 2017, 467, 34-41.	0.5	96
14	Association of Cardiovascular Risk Factors and Disease With Depression in Later Life. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 506-513.	0.6	94
15	Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. <i>Bone</i> , 2009, 45, 870-875.	1.4	89
16	A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. <i>Bone</i> , 2004, 34, 747-754.	1.4	83
17	Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. <i>Neurobiology of Aging</i> , 2005, 26, 251-257.	1.5	81
18	Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. <i>British Journal of Cancer</i> , 1993, 67, 560-563.	2.9	77

#	ARTICLE	IF	CITATIONS
19	Clinical Utility and Measurement of Procalcitonin. <i>Clinical Biochemist Reviews</i> , 2017, 38, 59-68.	3.3	74
20	Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2008, 45, 221-258.	2.7	69
21	Quality Assessment of Interpretative Commenting in Clinical Chemistry. <i>Clinical Chemistry</i> , 2004, 50, 632-637.	1.5	67
22	Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. <i>Annals of Clinical Biochemistry</i> , 2003, 40, 546-551.	0.8	66
23	Subjective Memory Complaints With and Without Objective Memory Impairment: Relationship With Risk Factors for Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 731-734.	0.6	65
24	Secondary hypoadrenalism presenting with hypercalcaemia. <i>Clinical Endocrinology</i> , 1994, 41, 261-264.	1.2	63
25	Cardiovascular disease and osteoporosis: is there a link between lipids and bone?. <i>Annals of Clinical Biochemistry</i> , 2002, 39, 203-210.	0.8	50
26	Assuring the quality of interpretative comments in clinical chemistry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1901-1911.	1.4	49
27	Reference Intervals for Bone Turnover Markers and Their Association With Incident Hip Fractures in Older Men: The Health In Men Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 90-99.	1.8	48
28	Alendronate in the treatment of Paget's disease of bone. <i>Bone</i> , 1997, 20, 263-271.	1.4	44
29	Cardiac troponin increases among marathon runners in the Perth Marathon: the Troponin in Marathons (TRIM) study. <i>Medical Journal of Australia</i> , 2009, 190, 91-93.	0.8	41
30	Official Positions for FRAX <sup>®</sup> Clinical Regarding Biochemical Markers. <i>Journal of Clinical Densitometry</i> , 2011, 14, 220-222.	0.5	41
31	B-vitamins reduce plasma levels of beta amyloid. <i>Neurobiology of Aging</i> , 2008, 29, 303-305.	1.5	40
32	Parathyroid Hormone Is More Stable in EDTA Plasma Than in Serum. <i>Clinical Chemistry</i> , 2002, 48, 766-767.	1.5	39
33	Decision limit for troponin I and assay performance. <i>Annals of Clinical Biochemistry</i> , 2002, 39, 231-236.	0.8	37
34	Association Between Homocysteine, Depression, and Cognitive Function in Community-Dwelling Older Women from Australia. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 327-328.	1.3	36
35	The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. <i>Endocrine</i> , 2016, 52, 222-225.	1.1	34
36	Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein – A position paper from the IFCC Committee on bone metabolism. <i>Clinica Chimica Acta</i> , 2021, 517, 171-197.	0.5	33

#	ARTICLE	IF	CITATIONS
37	Sustained response to intravenous alendronate in postmenopausal osteoporosis. <i>Bone</i> , 1995, 17, 517-520.	1.4	32
38	Efficacy of B Vitamins in Lowering Homocysteine in Older Men. <i>Stroke</i> , 2006, 37, 547-549.	1.0	31
39	Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and $\text{I}^2\text{-CTX}$ in blood. <i>Clinica Chimica Acta</i> , 2021, 515, 16-20.	0.5	31
40	Faecal Calprotectin. <i>Clinical Biochemist Reviews</i> , 2018, 39, 77-90.	3.3	30
41	Subjective memory complaints with and without objective memory impairment: relationship with risk factors for dementia. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 731-4.	0.6	28
42	The effects of intravenous alendronate in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1094-1100.	3.1	27
43	Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. <i>Clinica Chimica Acta</i> , 2001, 306, 63-69.	0.5	26
44	Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. <i>Clinical Science</i> , 2002, 102, 631-637.	1.8	25
45	Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. <i>Clinica Chimica Acta</i> , 2018, 481, 161-170.	0.5	25
46	Improved technical success and radiation safety of adrenal vein sampling using rapid, semi-quantitative point-of-care cortisol measurement. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 588-592.	0.8	25
47	A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1546-1555.	1.4	25
48	Preanalytical Factors in the Measurement of Intact Parathyroid Hormone with the DPC IMMULITE Assay. <i>Clinical Chemistry</i> , 2002, 48, 566-567.	1.5	24
49	Review of a pilot quality-assessment program for interpretative comments. <i>Annals of Clinical Biochemistry</i> , 2002, 39, 250-260.	0.8	24
50	Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults. <i>Clinical Biochemist Reviews</i> , 2014, 35, 237-42.	3.3	24
51	Outliers affecting cardiac troponin I measurement: comparison of a new high sensitivity assay with a contemporary assay on the Abbott ARCHITECT analyser. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 476-484.	0.8	23
52	Vitamin D insufficiency and hyperparathyroidism in Perth blood donors. <i>Medical Journal of Australia</i> , 2000, 172, 406-407.	0.8	22
53	Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates. <i>Journal of Oral and Maxillofacial Surgery</i> , 2009, 67, 645-649.	0.5	22
54	25-Hydroxyvitamin D C3-epimer is universally present in neonatal Western Australian samples but is unlikely to contribute to diagnostic misclassification. <i>Annals of Clinical Biochemistry</i> , 2016, 53, 593-598.	0.8	22

#	ARTICLE	IF	CITATIONS
55	A diagnostic conundrum: heterophilic antibody interference in an adrenocorticotrophic hormone immunoassay not detectable using a proprietary heterophile blocking reagent. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 433-437.	0.8	20
56	Comparison of results from commercial assays for plasma CTX: The need for harmonization. <i>Clinical Biochemistry</i> , 2015, 48, 519-524.	0.8	19
57	Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. <i>Clinical Science</i> , 2002, 102, 631.	1.8	18
58	Quality of interpretative commenting on common clinical chemistry results in the Asia-Pacific region and Africa. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 963-70.	1.4	18
59	Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays – an update from the Canadian society of clinical chemists (CSCC); the case for age related acute myocardial infarction (AMI) cut-offs. <i>Clinical Biochemistry</i> , 2012, 45, 513-514.	0.8	18
60	An audit of management of patients with borderline increased plasma-free metanephrines. <i>Annals of Clinical Biochemistry</i> , 2010, 47, 554-558.	0.8	16
61	Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. <i>Postgraduate Medical Journal</i> , 2013, 89, 617-620.	0.9	16
62	Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis. <i>Calcified Tissue International</i> , 2023, 112, 148-157.	1.5	16
63	The Role of PINP in Diagnosis and Management of Metabolic Bone Disease. , 2021, 42, 3-10.		14
64	The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM. <i>Clinica Chimica Acta</i> , 2021, 515, 44-51.	0.5	14
65	Harmonization of commercial assays for PINP; the way forward. <i>Osteoporosis International</i> , 2020, 31, 409-412.	1.3	13
66	Analytical Performance Specifications for 25-Hydroxyvitamin D Examinations. <i>Nutrients</i> , 2021, 13, 431.	1.7	13
67	Major method-specific differences in the measurement of intact parathyroid hormone: studies in patients with and without chronic renal failure. <i>Annals of Clinical Biochemistry</i> , 2004, 41, 149-154.	0.8	12
68	Standardising biochemical assessment of bone turnover in osteoporosis. <i>Clinical Biochemistry</i> , 2011, 44, 1033-1034.	0.8	12
69	Towards optimising the provision of laboratory services for bone turnover markers. <i>Pathology</i> , 2014, 46, 267-273.	0.3	12
70	High-sensitivity Cardiac Troponin I Improves Cardiovascular Risk Prediction in Older Men: HIMS (The) Tj ETQq0 0 0 rgBT / Overlock 10 T	1.6	12
71	Association of low-energy femoral fractures with prolonged bisphosphonate use: a case-control study. <i>Osteoporosis International</i> , 2009, 20, 1457-1458.	1.3	11
72	Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2. <i>Clinica Chimica Acta</i> , 2009, 404, 144-148.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Anatomy and history of an external quality assessment program for interpretative comments in clinical biochemistry. <i>Clinical Biochemistry</i> , 2015, 48, 467-471.	0.8	11
74	The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. <i>Clinical Biochemist Reviews</i> , 2006, 27, 119-21.	3.3	11
75	Vitamin D Status and Redefining Serum PTH Reference Range in the Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 946-947.	1.8	10
76	Assessment of bone turnover in osteoporosis: harmonization of the total testing process. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1603-1607.	1.4	10
77	Bone turnover marker monitoring in osteoporosis treatment response. <i>European Journal of Endocrinology</i> , 2020, 183, C5-C7.	1.9	10
78	Comparison of clinical cut-points and treatment targets for urine NTX and plasma $\hat{1}^2$ CTX-I in osteoporosis. <i>Clinical Biochemistry</i> , 2016, 49, 529-533.	0.8	9
79	A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen ( $\hat{1}^2$ -CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). <i>Calcified Tissue International</i> , 2021, 108, 785-797.	1.5	9
80	Comparison of 8 methods for univariate statistical exclusion of pathological subpopulations for indirect reference intervals and biological variation studies. <i>Clinical Biochemistry</i> , 2022, 103, 16-24.	0.8	9
81	Ischaemia modified albumin cannot be used for rapid exclusion of acute coronary syndrome. <i>Emergency Medicine Journal</i> , 2010, 27, 668-671.	0.4	8
82	Recommendations for bone marker standards in osteoporosis: what, why and where to now?. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 91-92.	0.8	8
83	Bone turnover markers: Defining a therapeutic target. <i>Clinical Biochemistry</i> , 2017, 50, 162-163.	0.8	8
84	Parathyroid hormone is more stable in EDTA plasma than in serum. <i>Clinical Chemistry</i> , 2002, 48, 766-7.	1.5	8
85	The effect of alendronate on renal tubular reabsorption of phosphate. <i>Bone and Mineral</i> , 1994, 27, 51-56.	2.0	7
86	A high pressure liquid chromatography method for separation of prolactin forms. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 285-288.	0.8	7
87	High-sensitivity cardiac troponin assays for risk stratification and for the diagnosis of acute myocardial infarction. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 209-210.	0.8	7
88	Therapeutic efficiency of tirofiban in acute coronary syndromes. <i>Lancet, The</i> , 2000, 355, 929-930.	6.3	6
89	Homocysteine and vitamin status in older people in Perth. <i>Medical Journal of Australia</i> , 2004, 180, 539-540.	0.8	6
90	Preanalytical factors in the measurement of intact parathyroid hormone with the DPC IMMULITE assay. <i>Clinical Chemistry</i> , 2002, 48, 566-7.	1.5	6

#	ARTICLE	IF	CITATIONS
91	A discussion of cases in the 2001 RCPA-AQAP Chemical Pathology Case Report Comments Program. Pathology, 2003, 35, 145-150.	0.3	5
92	Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospital. Pathology, 2006, 38, 49-52.	0.3	5
93	Salivary paracetamol: evaluation of a colorimetric method in assessing deliberate self-poisoning. Annals of Clinical Biochemistry, 2009, 46, 149-151.	0.8	5
94	An audit of oral glucose tolerance tests at a large teaching hospital: indications, outcomes and confounding factors. Annals of Clinical Biochemistry, 2009, 46, 390-393.	0.8	5
95	Short- and long-term biological variation of cardiac troponin I in healthy individuals, and patients with end-stage renal failure requiring haemodialysis or cardiomyopathy. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1941-1949.	1.4	5
96	Comparison of four indirect (data mining) approaches to derive within-subject biological variation. Clinical Chemistry and Laboratory Medicine, 2022, .	1.4	5
97	A discussion of cases in the 2001 RCPA-AQAP Chemical Pathology Case Report Comments Program. Pathology, 2003, 35, 145-50.	0.3	5
98	C-reactive protein: a new cardiovascular risk factor?. Medical Journal of Australia, 2000, 173, 117-118.	0.8	4
99	Surgically correctable hypertension. Pathology, 2002, 34, 297-298.	0.3	4
100	Spot urine analysis: acidification does not increase calcium recovery. Annals of Clinical Biochemistry, 2002, 39, 64-65.	0.8	4
101	Hypercalcemia Differential Diagnosis and Investigation. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 11-24.	1.3	4
102	Proficiency Testing of Hb A1c: A 4-Year Experience in Taiwan and the Asian Pacific Region. Clinical Chemistry, 2009, 55, 1876-1880.	1.5	4
103	Is vitamin D testing at a tertiary referral hospital consistent with guideline recommendations?. Pathology, 2015, 47, 335-340.	0.3	4
104	Measurement and Clinical Utility of $^{125}\text{I}$ CTX in Serum and Plasma. Advances in Clinical Chemistry, 2017, 81, 97-134.	1.8	4
105	The challenge of improving the diagnostic yield from metanephrine testing in suspected pheochromocytoma and paraganglioma. Annals of Clinical Biochemistry, 2018, 55, 679-684.	0.8	4
106	Measuring performance. Clinical Biochemist Reviews, 2011, 32, 3-4.	3.3	4
107	A discussion of cases in the 2001 RCPA-AQAP Chemical Pathology Case Report Comments Program. Pathology, 2003, 35, 145-150.	0.3	3
108	Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 12-13.	2.9	2

#	ARTICLE	IF	CITATIONS
109	The role of the laboratory in investigation and management of bone disease. <i>Clinical Biochemistry</i> , 2012, 45, 861-862.	0.8	2
110	Impact of the Australian gender specific thresholds using the Abbott high sensitivity troponin I assay in clinical care. <i>Pathology</i> , 2017, 49, 514-517.	0.3	2
111	Bone Turnover Markers. , 2018, , 116-127.		2
112	Lead poisoning due to traditional herbal preparations. <i>Medical Journal of Australia</i> , 1993, 158, 292-292.	0.8	2
113	Interpretative commenting. <i>Clinical Biochemist Reviews</i> , 2008, 29 Suppl 1, S99-S103.	3.3	2
114	Measuring myocardial damage. <i>Medical Journal of Australia</i> , 2001, 174, 163-164.	0.8	1
115	Interpretative commenting in clinical chemistry with worked examples for thyroid function test reports. <i>Practical Laboratory Medicine</i> , 2021, 26, e00243.	0.6	1
116	Suboptimal management of subclinical hypothyroidism. <i>Medical Journal of Australia</i> , 2004, 181, 232-232.	0.8	0
117	Directions for clinical practice improvement in HFE gene mutation testing. <i>Medical Journal of Australia</i> , 2007, 187, 342-344.	0.8	0
118	The role of the laboratory in ensuring appropriate testing. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 283-284.	0.8	0
119	High-sensitivity troponin in marathon runners. <i>Medical Journal of Australia</i> , 2013, 199, 169-170.	0.8	0